Coherus Biosciences traded at $7.78 this Friday May 13th, increasing $0.19 or 2.50 percent since the previous trading session. Looking back, over the last four weeks, Coherus Biosciences gained 33.10 percent. Over the last 12 months, its price fell by 43.99 percent. Looking ahead, we forecast Coherus Biosciences to be priced at 7.59 by the end of this quarter and at 7.06 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
7.78
Daily Change
2.50%
Yearly
-43.99%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
LG Chem 485,500.00 0 0% -42.88%
Fujifilm 7,039.00 9.00 0.13% 2.00%
AbbVie 153.14 -1.16 -0.75% 31.53%
Acadia Pharmaceuticals 16.53 0.50 3.09% -22.13%
Aerie Pharmaceuticals 6.56 0.11 1.71% -63.29%
Akebia Therapeutics 0.45 0.03 7.92% -86.62%
ALKERMES 26.82 0.25 0.94% 20.59%
Alnylam Pharmaceuticals 127.85 6.52 5.37% -3.82%
Amgen 243.49 -1.23 -0.50% -3.14%
Amarin 1.49 0.24 19.20% -65.98%
Baxter International 73.03 0.38 0.52% -12.91%
Biogen 198.99 4.67 2.40% -28.99%
Bluebird Bio 3.48 0.11 3.26% -88.13%
BioMarin Pharmaceutical 78.04 1.66 2.17% 3.34%
Bristol-Myers Squibb 75.80 -0.50 -0.66% 16.83%
Coherus Biosciences 7.78 0.19 2.50% -43.99%
Endo International 1.21 0.08 6.64% -78.52%
Gilead Sciences 62.32 -0.17 -0.26% -9.07%
Horizon Pharma 90.46 2.47 2.81% -1.82%
Ironwood Pharmaceuticals 11.69 -0.05 -0.38% 1.79%
Jazz Pharmaceuticals 144.94 2.13 1.49% -18.65%
Eli Lilly 291.50 -0.30 -0.10% 48.57%
Merck & Co 90.38 -0.39 -0.43% 15.44%
Myriad Genetics 21.49 0.61 2.90% -16.24%
Pacira 61.88 0.74 1.21% 0.68%
Pfizer 49.87 -0.53 -1.04% 24.60%
Perrigo 36.81 1.56 4.41% -19.74%
PTC Therapeutics 31.40 0.55 1.78% -18.21%
Regeneron Pharmaceuticals 645.45 11.49 1.81% 24.94%
Revance Therapeutics 14.17 1.02 7.76% -49.19%
Sarepta Therapeutics 66.44 3.16 4.99% -8.37%
Teva Pharmaceutical Industries Ltd 2,562.00 -64.00 -2.44% -25.89%
Vertex Pharmaceuticals 246.53 5.68 2.36% 13.56%
Xencor 24.13 0.34 1.43% -37.41%
Zoetis 167.13 4.05 2.48% -2.18%

Indexes Price Day Year
USND 11805 434.04 3.82% -12.10%
US400 2431 61.02 2.57% -10.69%

Coherus Biosciences
Coherus BioSciences, Inc. is a commercial stage biotherapeutics company. The Company is focused on the biosimilar and immuno-oncology market primarily in the United States. The Company’s pipeline includes the four categories product candidates, Oncology pipeline, Immunology pipeline, Ophthalmology pipeline and Small Molecule pipeline. Oncology pipeline includes Toripalimab, an anti-PD-1 antibody; UDENYCA (pegfilgrastim-cbqv); CHS-305, a bevacizumab (Avastin) biosimilar. Immunology pipeline includes CHS-1420, an anti-TNF product candidate, as an adalimumab (Humira) biosimilar. Ophthalmology pipeline includes CHS-201, a ranibizumab (Lucentis) biosimilar. CHS-201, a ranibizumab (Lucentis) biosimilar. Small Molecule pipeline includes CHS-131, an oral, small-molecule drug candidate. CHS-131 is a once-daily oral drug candidate for non-alcoholic steatohepatitis (NASH) and other metabolic conditions.